1993
DOI: 10.1016/0360-3016(93)90299-b
|View full text |Cite
|
Sign up to set email alerts
|

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Preliminary results of a randomized, open-labeled, phase II trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
9
0
1

Year Published

1995
1995
2006
2006

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 54 publications
(11 citation statements)
references
References 23 publications
1
9
0
1
Order By: Relevance
“…These findings in our randomized study confirm the erythropoietic effect of r-HuEPO demonstrated in previous non-randomized studies of anaemic cancer patients undergoing RT as well as our preliminary report (Lavey and Dempsey, 1993;Vijayakumar et al, 1993;Dusenbery et al, 1994). Lavey and Dempsey (1993) described an improvement in mean haemoglobin level from 11.9 g dl-' to 15.1 g dl-' in 20 patients who received r-HuEPO while undergoing RT for supradiaphragmatic tumours (Kushner, 1992).…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…These findings in our randomized study confirm the erythropoietic effect of r-HuEPO demonstrated in previous non-randomized studies of anaemic cancer patients undergoing RT as well as our preliminary report (Lavey and Dempsey, 1993;Vijayakumar et al, 1993;Dusenbery et al, 1994). Lavey and Dempsey (1993) described an improvement in mean haemoglobin level from 11.9 g dl-' to 15.1 g dl-' in 20 patients who received r-HuEPO while undergoing RT for supradiaphragmatic tumours (Kushner, 1992).…”
Section: Discussionsupporting
confidence: 92%
“…Recombinant erythropoietin (r-HuEPO) has previously been shown to increase the haematocrit and reduce the transfusion requirement in patients with end-stage renal disease undergoing haemodialysis (Esbach et al, 1989) and in AIDS patients treated with zidovudine (Fischl et al, 1990). In addition, there are now a number of reports on the use of r-HuEPO to correct anaemia in cancer patients (Platanias et al, 1991;Abels, 1992aAbels, ,b, 1993Miller et al, 1992;Case et al, 1993;Lavey and Dempsey, 1993;Ludwig et al, 1993Ludwig et al, , 1994Vijayakumar et al, 1993;Dusenbery et al, 1994;Leitgeh et al, 1994;deCampos et al, 1995). In the largest randomized trial published to date, Abels (1993) demonstrated that r-HuEPO corrected anaemia and reduced transfusion requirements compared with a control group for patients with a variety of cancers undergoing chemotherapy.…”
mentioning
confidence: 99%
“…However, many of the published QoL studies in anaemic cancer patients have tended to employ generic and non-specific scales such as the WHO Performance Status Indicator (Ludwig et al, 1993;Mittelman et al, 1997) and the Linear Analogue Scale Assessment (LASA, also known as CLAS, Cancer Linear Analogue Scale) (Abels, 1992(Abels, , 1993Case et al, 1993;Vijayakumar et al, 1993;Glaspy et al, 1997).…”
mentioning
confidence: 99%
“…Most studies of the effect of rhEPO on the anaemic state during radiotherapy have generally only focused on changes in RBCrelated parameters (Lavey et al, 1993;Vijayakumar et al, 1993) and did not examine changes in radiosensitivity. Only Joiner et al (1993) used rhEPO to correct a tumour-associated anaemia and measured radiosensitivity in anaemic animals as well as in mice in which anaemia was treated with different doses of rhEPO.…”
mentioning
confidence: 99%